Nicolas Kuritzky, MD
Radiation Oncology · Miami Beach, FLNPI 1013935477
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,918 of the $6,442 with a category attached, or 76.3%. 43 manufacturers reported payments, led by Novocure Inc. at 29.2% of the total. Reporting peaked in 2022 at $2,434 and has fallen 70.4% since, to $721 in 2025.
Across 209 payments — averaging $30.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- Sumitomo Pharma America, Inc.$668
- Amgen$420
- Pfizer$373
- Merck$342
- Boston Scientific$266
- plus $2K from 37 others
Across 13 payments — averaging $5121.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$51K
- Novocure Inc.$16K
What the payments were for
- Consulting fees$1,50023%
- Food & beverage$4,91876%
- Education$240%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 10 | $1,883 |
| Sumitomo Pharma America, Inc. | 28 | $668 |
| Amgen | 26 | $420 |
| Pfizer | 18 | $373 |
| Merck | 18 | $342 |
| Boston Scientific | 5 | $266 |
| AstraZeneca | 11 | $238 |
| Myovant Sciences Inc. | 11 | $207 |
| Seagen Inc. | 13 | $206 |
| Myriad Genetic Laboratories, Inc. | 1 | $194 |
| Novartis | 7 | $156 |
| GT Medical Technologies, Inc | 2 | $141 |
| Sirtex Medical Inc | 3 | $138 |
| Tempus AI, Inc | 2 | $138 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $85 |
| Sanofi | 4 | $76 |
| Incyte Corporation | 4 | $68 |
| Eisai Inc. | 3 | $63 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Johnson & Johnson | 3 | $57 |
| Siemens Medical Solutions USA, Inc. | 2 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| EMD Serono, Inc. | 3 | $42 |
| Viewray Technologies Inc | 1 | $41 |
| AbbVie | 2 | $38 |
| Reflexion Medical, Inc. | 1 | $36 |
| Bristol Myers Squibb | 2 | $36 |
| Gilead | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $32 |
| GSK | 2 | $26 |
| Bayer | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $22 |
| Elekta, Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Exelixis Inc. | 1 | $20 |
| Ambu Inc. | 1 | $20 |
| Deciphera Pharmaceuticals Inc. | 1 | $20 |
| Morphosys, US Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prolaris$194
- SpaceOAR VUE System - 10mL$166
- XT CDX$121
- Optune$120
- GammaTile$110
How this compares
$6,442 in reported general payments places this provider in the 85th percentile of 465 radiation oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 48 | $130,309 |
| OzempicSemaglutide | 11 | $10,468 |
| Tadalafil | 17 | $3,073 |
| Tamsulosin Hcl | 154 | $1,079 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 37 | $658 |
| Dexamethasone | 81 | $642 |
| Pregabalin | 25 | $480 |
| Gabapentin | 16 | $181 |
| Lidocaine Hcl ViscousLidocaine Hcl | 11 | $148 |
| Meloxicam | 53 | $122 |
| Trazodone Hcl | 13 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $668 | $130,30948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 465 radiation oncology providers in Florida.
Other radiation oncology in Miami Beach
- Shravan KandulaOrlando$444K
- Martin KeischMiami Shores$319K
- Marcio FagundesMiami$274K
- Evan ThomasWinter Park$209K
- Rupesh KotechaMiami$208K
- John SylvesterLakewood Ranch$205K
- Ravi ShridharOrlando$192K
- Alan BrownFort Myers$165K
- Akash NandaOrlando$165K
- Michael ChuongMiami$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.